Log In
BCIQ
Print this Print this
 

Neuroblastoma vaccine

  Manage Alerts
Collapse Summary General Information
Company MabVax Therapeutics Holdings Inc.
DescriptionBivalent vaccine that elicits an antibody response targeting the 2 most common antigens on neuroblastoma cells
Molecular Target
Mechanism of ActionVaccine
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationNeuroendocrine tumors
Indication DetailsTreat neuroblastoma
Regulatory Designation U.S. - Orphan Drug (Treat neuroblastoma)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/09/2014

Undisclosed

0

0

Get a free BioCentury trial today